Imcivree
(Setmelanotide)ApprovedPeptide
Rhythm PharmaceuticalsSetmelanotide is used to treat rare genetic forms of obesity caused by specific mutations in genes that control appetite and metabolism. It helps reduce weight and food cravings in people with these genetic conditions.[2] Imcivree is currently approved and in use across 10 indications[4].[1]
Imcivree is one of 151 peptide programs targeting Genetic obesity. It is currently in Approved.
10
Indications
22
Total Trials
6
Active Trials
150
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
3
Patents
Pipeline
Status by Indication[4][1]
Indication
Competition
Competitive Landscape
392 competitors in Obesity
#DrugCompanyPhaseTrials
1Imcivree
Rhythm PharmaceuticalsApproved
Actemra
RochePreclinical
Avapro
SanofiPreclinical
Calciferol
Alnylam PharmaceuticalsPreclinical
Amidate
PfizerPreclinical
Adenocard
AstellasPreclinical
Activella
Eli LillyPreclinical
Oxycontin
PProtega
Preclinical
EGRIFTA WR
TTheratechnologies
Preclinical
Advil
KKenvue Brands
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Hypothalamic Obesity3 trials
Obesity3 trials
Bardet-Biedl syndrome2 trials
Trial2 trials
7 more indications
Safety and Efficacy2 trials
ART2 trials
Genetic Disorder1 trial
Renal Impairment1 trial
Bardet Biedl Syndrome (BBS)1 trial
Regulatory
FDA Approval Timeline[5]
Nov 25, 2020
IMCIVREE
NDA NDA213793
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Imcivree drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Setmelanotide. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
- [7]
- [8]